Switch to:
Also traded in: Austria, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.06
WBA's Cash-to-Debt is ranked lower than
80% of the 373 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.55 vs. WBA: 0.06 )
Ranked among companies with meaningful Cash-to-Debt only.
WBA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03  Med: 1.12 Max: No Debt
Current: 0.06
0.03
No Debt
Equity-to-Asset 0.37
WBA's Equity-to-Asset is ranked lower than
53% of the 371 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.41 vs. WBA: 0.37 )
Ranked among companies with meaningful Equity-to-Asset only.
WBA' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.37  Med: 0.55 Max: 0.64
Current: 0.37
0.37
0.64
Debt-to-Equity 0.62
WBA's Debt-to-Equity is ranked higher than
51% of the 292 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.55 vs. WBA: 0.62 )
Ranked among companies with meaningful Debt-to-Equity only.
WBA' s Debt-to-Equity Range Over the Past 10 Years
Min: 0  Med: 0.16 Max: 0.7
Current: 0.62
0
0.7
Debt-to-EBITDA 2.00
WBA's Debt-to-EBITDA is ranked higher than
55% of the 291 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.18 vs. WBA: 2.00 )
Ranked among companies with meaningful Debt-to-EBITDA only.
WBA' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.48  Med: 1.1 Max: 2.48
Current: 2
0.48
2.48
Interest Coverage 9.79
WBA's Interest Coverage is ranked lower than
70% of the 326 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 18.97 vs. WBA: 9.79 )
Ranked among companies with meaningful Interest Coverage only.
WBA' s Interest Coverage Range Over the Past 10 Years
Min: 7.2  Med: 22.3 Max: 55.37
Current: 9.79
7.2
55.37
Piotroski F-Score: 7
Altman Z-Score: 3.78
Beneish M-Score: -2.62
WACC vs ROIC
7.01%
12.74%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 4.57
WBA's Operating Margin % is ranked higher than
67% of the 375 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.88 vs. WBA: 4.57 )
Ranked among companies with meaningful Operating Margin % only.
WBA' s Operating Margin % Range Over the Past 10 Years
Min: 4.21  Med: 4.9 Max: 5.45
Current: 4.57
4.21
5.45
Net Margin % 3.96
WBA's Net Margin % is ranked higher than
65% of the 375 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.97 vs. WBA: 3.96 )
Ranked among companies with meaningful Net Margin % only.
WBA' s Net Margin % Range Over the Past 10 Years
Min: 2.53  Med: 3.49 Max: 4.08
Current: 3.96
2.53
4.08
ROE % 20.08
WBA's ROE % is ranked higher than
67% of the 365 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 9.14 vs. WBA: 20.08 )
Ranked among companies with meaningful ROE % only.
WBA' s ROE % Range Over the Past 10 Years
Min: 9.67  Med: 14.38 Max: 20.08
Current: 20.08
9.67
20.08
ROA % 7.70
WBA's ROA % is ranked higher than
66% of the 376 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.77 vs. WBA: 7.70 )
Ranked among companies with meaningful ROA % only.
WBA' s ROA % Range Over the Past 10 Years
Min: 5.31  Med: 7.44 Max: 10.1
Current: 7.7
5.31
10.1
ROC (Joel Greenblatt) % 44.30
WBA's ROC (Joel Greenblatt) % is ranked higher than
84% of the 374 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 14.33 vs. WBA: 44.30 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
WBA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 24.31  Med: 27.12 Max: 45.17
Current: 44.3
24.31
45.17
3-Year Revenue Growth Rate 10.40
WBA's 3-Year Revenue Growth Rate is ranked higher than
80% of the 343 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.70 vs. WBA: 10.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
WBA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -10.3  Med: 11.6 Max: 46.5
Current: 10.4
-10.3
46.5
3-Year EBITDA Growth Rate 11.60
WBA's 3-Year EBITDA Growth Rate is ranked lower than
55% of the 312 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 6.50 vs. WBA: 11.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
WBA' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -8.3  Med: 13 Max: 47.1
Current: 11.6
-8.3
47.1
3-Year EPS without NRI Growth Rate 8.10
WBA's 3-Year EPS without NRI Growth Rate is ranked higher than
76% of the 288 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 9.30 vs. WBA: 8.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
WBA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -12.1  Med: 15.1 Max: 129.6
Current: 8.1
-12.1
129.6
GuruFocus has detected 3 Warning Signs with Walgreens Boots Alliance Inc WBA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» WBA's 30-Y Financials

Financials (Next Earnings Date: 2019-03-28)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2018

WBA Guru Trades in Q1 2018

Steven Cohen 230,000 sh (New)
Robert Olstein 159,300 sh (+10.63%)
John Buckingham 33,698 sh (+20.89%)
Paul Tudor Jones 150,547 sh (+300.54%)
Larry Robbins 8,184,927 sh (+19.84%)
Mario Gabelli 491,496 sh (+7.87%)
Vanguard Health Care Fund 8,048,160 sh (unchged)
David Dreman 6,324 sh (unchged)
Dodge & Cox 5,669 sh (unchged)
Tom Gayner 2,135,000 sh (unchged)
Bill Gates 3,475,398 sh (unchged)
Smead Value Fund 831,982 sh (unchged)
George Soros Sold Out
Tom Russo Sold Out
Jim Simons Sold Out
First Pacific Advisors Sold Out
Ken Fisher 6,904 sh (-25.88%)
Joel Greenblatt 394,680 sh (-35.73%)
John Hussman 20,000 sh (-20.00%)
Mairs and Power 10,450 sh (-28.25%)
Caxton Associates 13,700 sh (-6.40%)
Pioneer Investments 1,347,623 sh (-18.35%)
Ray Dalio 314,587 sh (-20.13%)
» More
Q2 2018

WBA Guru Trades in Q2 2018

Robert Olstein 180,000 sh (+12.99%)
Joel Greenblatt 584,157 sh (+48.01%)
Tom Gayner 2,148,000 sh (+0.61%)
Steven Cohen 315,000 sh (+36.96%)
Pioneer Investments 1,433,050 sh (+6.34%)
Ray Dalio 657,649 sh (+109.05%)
Vanguard Health Care Fund 8,048,160 sh (unchged)
Dodge & Cox 5,669 sh (unchged)
John Hussman 20,000 sh (unchged)
Bill Gates 3,475,398 sh (unchged)
Mairs and Power 10,450 sh (unchged)
Caxton Associates Sold Out
Ken Fisher 5,498 sh (-20.37%)
John Buckingham 32,615 sh (-3.21%)
Paul Tudor Jones 15,608 sh (-89.63%)
Larry Robbins 7,022,969 sh (-14.20%)
Mario Gabelli 457,738 sh (-6.87%)
Smead Value Fund 826,632 sh (-0.64%)
» More
Q3 2018

WBA Guru Trades in Q3 2018

Pioneer Investments 2,341,823 sh (+63.42%)
John Buckingham 32,754 sh (+0.43%)
Smead Value Fund 914,616 sh (+10.64%)
John Hussman 20,000 sh (unchged)
Vanguard Health Care Fund 8,048,160 sh (unchged)
Tom Gayner 2,148,000 sh (unchged)
Mairs and Power 10,450 sh (unchged)
Bill Gates 3,475,398 sh (unchged)
Dodge & Cox 5,669 sh (unchged)
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
Ken Fisher 4,544 sh (-17.35%)
Mario Gabelli 202,842 sh (-55.69%)
Robert Olstein 140,700 sh (-21.83%)
Ray Dalio 112,587 sh (-82.88%)
Larry Robbins 3,875,231 sh (-44.82%)
Joel Greenblatt 443,704 sh (-24.04%)
» More
Q4 2018

WBA Guru Trades in Q4 2018

Caxton Associates 4,063 sh (New)
Paul Tudor Jones 23,981 sh (New)
John Hussman 51,000 sh (+155.00%)
Pioneer Investments 2,683,417 sh (+14.59%)
Joel Greenblatt 468,963 sh (+5.69%)
Tom Gayner 2,148,000 sh (unchged)
Bill Gates 3,475,398 sh (unchged)
Ken Fisher 3,480 sh (-23.42%)
Vanguard Health Care Fund 5,732,860 sh (-28.77%)
Mario Gabelli 149,200 sh (-26.45%)
Smead Value Fund 891,181 sh (-2.56%)
Robert Olstein 94,000 sh (-33.19%)
Ray Dalio 46,141 sh (-59.02%)
Mairs and Power 10,150 sh (-2.87%)
Dodge & Cox 5,469 sh (-3.53%)
Larry Robbins 961,747 sh (-75.18%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:WBA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Retail - Defensive » Pharmaceutical Retailers    NAICS: 446110    SIC: 5912
Compare:TSE:3391, BSP:RADL3, TSE:9989, SHSE:600998, TSE:3141, TSE:3088, TSE:3349, JSE:CLS, SSE:2928, TSE:7649, TSX:PJC.A, SHSE:603883, SHSE:603939, SZSE:002727, JSE:DCP, TSE:9627, TSE:3549, TSE:3148, TSE:3098, NYSE:RAD » details
Traded in other countries:WBA.Austria, W8A.Germany, WBA.Mexico, WBA.Switzerland, 0LSZ.UK,
Headquarter Location:USA
Walgreens Boots Alliance Inc is a pharmacy led health and wellbeing company. It operates retail pharmacy store chain in the United States. The firm sells and markets its products under brands such as Walgreens, Duane Reade, Boots and Alliance Healthcare.

Walgreens is one of the nation's largest retail pharmacies, with about 8,100 drugstores throughout the United States. The firm recently acquired half of Rite Aid's locations, which will push its store count to approximately 10,000. This large network of stores enables the firm to reach a significant portion of the U.S. population, providing excellent brand recognition. Prescription drugs account for about two thirds of sales, with the balance attributable to front-store products such as grocery, health, and beauty items.

Top Ranked Articles about Walgreens Boots Alliance Inc

Alipay, The World's Leading Digital Payment Platform, Now Available at Thousands of Walgreens Stores Nationwide
US Market Indexes End Slightly Lower Friday S&P 500 gains 2.4% for the week
The Dow Jones Industrial Average closed at 23,995.95 on Friday with a loss of 5.97 points or -0.02%. The S&P 500 closed at 2,596.26 for a loss of 0.38 points or -0.01%. The Nasdaq Composite closed at 6,971.48 for a loss of 14.59 points or -0.21%. The VIX Volatility Index was lower at 18.21 for a loss of 1.29 points or -6.62%. Read more...
US Market Indexes Continue Losses Thursday S&P 500 closes at 2467.42 for a loss of -1.58%
The Dow Jones Industrial Average closed at 22859.60 on Thursday with a loss of -464.06 points or -1.99%. The S&P 500 closed at 2467.42 for a loss of -39.54 points or -1.58%. The Nasdaq Composite closed at 6528.41 for a loss of -108.42 points or -1.63%. The VIX Volatility Index was higher at 28.38 for a gain of 2.80 points or 10.95%. Read more...
Walgreens Shares Slide on $1 Billion Cost-Savings Program Company posts earnings, revenue beat
Drugstore chain Walgreens Boots Alliance Inc. (NASDAQ:WBA) reported solid first-quarter 2019 earnings before the opening bell on Thursday, but a multiyear plan to cut costs by $1 billion sent shares lower. Read more...
Why Walgreens Boots Alliance Has Growth Potential The company appears to have a sound strategy
An improved strategy that focuses on enhancing the customer experience could boost the stock performance of Walgreens Boots Alliance Inc. (NASDAQ:WBA). The company is focused on increasing its investment in omnichannel capabilities, while introducing new store concepts as it expands its store estate. Read more...
5 Companies Hit 52-Week Highs Recently, multiple companies have managed to achieve yearly highs
According to GuruFocus list of 52-week highs, these Guru stocks have reached their 52-Week Highs. Read more...
Walgreens and McLaren Health Care Announce Health Services and Pharmacy Collaboration
After Initial Decline, Walgreens Rises on 4th-Quarter Earnings Beat Company posts disappointing sales growth
Drugstore chain Walgreens Boots Alliance Inc. (NASDAQ:WBA) reported strong fourth-quarter earnings before the opening bell on Thursday, but disappointing revenue sent shares lower in premarket trading. Read more...
Introducing No7 Laboratories Line Correcting Booster Serum, the NEW non-invasive wrinkle solution, clinically proven to reduce the appearance of wrinkles by up to 5 years in 12 weeks
Weekly Top Insider Buys Highlight for the Week of July 20 The largest Insider Buys this week were for Walgreens Boots Alliance Inc. (WBA), DISH Network Corp. (DISH), Omnova Solutions Inc. (OMN), and Medical Properties Trust Inc. (MPW).
The largest Insider Buys this week were for Walgreens Boots Alliance Inc. (NASDAQ:WBA), DISH Network Corp. (NASDAQ:DISH), Omnova Solutions Inc. (NYSE:OMN), and Medical Properties Trust Inc. (NYSE:MPW). Read more...

Ratios

vs
industry
vs
history
PE Ratio 13.51
WBA's PE Ratio is ranked lower than
52% of the 303 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 18.85 vs. WBA: 13.51 )
Ranked among companies with meaningful PE Ratio only.
WBA' s PE Ratio Range Over the Past 10 Years
Min: 10.2  Med: 17.73 Max: 35.8
Current: 13.51
10.2
35.8
Forward PE Ratio 11.04
WBA's Forward PE Ratio is ranked higher than
81% of the 74 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 17.83 vs. WBA: 11.04 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 13.51
WBA's PE Ratio without NRI is ranked lower than
51% of the 303 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 19.28 vs. WBA: 13.51 )
Ranked among companies with meaningful PE Ratio without NRI only.
WBA' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.2  Med: 17.73 Max: 35.8
Current: 13.51
10.2
35.8
Price-to-Owner-Earnings 9.86
WBA's Price-to-Owner-Earnings is ranked higher than
76% of the 215 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 21.12 vs. WBA: 9.86 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
WBA' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 8.76  Med: 14.57 Max: 28.41
Current: 9.86
8.76
28.41
PB Ratio 2.71
WBA's PB Ratio is ranked lower than
66% of the 363 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.73 vs. WBA: 2.71 )
Ranked among companies with meaningful PB Ratio only.
WBA' s PB Ratio Range Over the Past 10 Years
Min: 1.6  Med: 2.64 Max: 3.5
Current: 2.71
1.6
3.5
PS Ratio 0.54
WBA's PS Ratio is ranked lower than
57% of the 367 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.48 vs. WBA: 0.54 )
Ranked among companies with meaningful PS Ratio only.
WBA' s PS Ratio Range Over the Past 10 Years
Min: 0.36  Med: 0.59 Max: 1.08
Current: 0.54
0.36
1.08
Price-to-Free-Cash-Flow 11.50
WBA's Price-to-Free-Cash-Flow is ranked higher than
71% of the 151 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 19.33 vs. WBA: 11.50 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
WBA' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 9.54  Med: 14.82 Max: 77.98
Current: 11.5
9.54
77.98
Price-to-Operating-Cash-Flow 9.33
WBA's Price-to-Operating-Cash-Flow is ranked higher than
53% of the 196 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 10.41 vs. WBA: 9.33 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
WBA' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.43  Med: 10.11 Max: 19.89
Current: 9.33
6.43
19.89
EV-to-EBIT 13.80
WBA's EV-to-EBIT is ranked higher than
50% of the 318 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 15.28 vs. WBA: 13.80 )
Ranked among companies with meaningful EV-to-EBIT only.
WBA' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.8  Med: 13.55 Max: 29
Current: 13.8
6.8
29
EV-to-EBITDA 10.62
WBA's EV-to-EBITDA is ranked higher than
51% of the 325 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 11.83 vs. WBA: 10.62 )
Ranked among companies with meaningful EV-to-EBITDA only.
WBA' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.3  Med: 10.3 Max: 20.9
Current: 10.62
5.3
20.9
EV-to-Revenue 0.64
WBA's EV-to-Revenue is ranked lower than
57% of the 365 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.58 vs. WBA: 0.64 )
Ranked among companies with meaningful EV-to-Revenue only.
WBA' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.4  Med: 0.6 Max: 1.3
Current: 0.64
0.4
1.3
PEG Ratio 1.36
WBA's PEG Ratio is ranked lower than
67% of the 177 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.19 vs. WBA: 1.36 )
Ranked among companies with meaningful PEG Ratio only.
WBA' s PEG Ratio Range Over the Past 10 Years
Min: 0.5  Med: 1.94 Max: 15.67
Current: 1.36
0.5
15.67
Shiller PE Ratio 21.85
WBA's Shiller PE Ratio is ranked lower than
57% of the 99 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 21.51 vs. WBA: 21.85 )
Ranked among companies with meaningful Shiller PE Ratio only.
WBA' s Shiller PE Ratio Range Over the Past 10 Years
Min: 13.88  Med: 22.85 Max: 36.74
Current: 21.85
13.88
36.74
Current Ratio 0.80
WBA's Current Ratio is ranked lower than
68% of the 351 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.20 vs. WBA: 0.80 )
Ranked among companies with meaningful Current Ratio only.
WBA' s Current Ratio Range Over the Past 10 Years
Min: 0.8  Med: 1.64 Max: 2.36
Current: 0.8
0.8
2.36
Quick Ratio 0.36
WBA's Quick Ratio is ranked lower than
72% of the 351 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.77 vs. WBA: 0.36 )
Ranked among companies with meaningful Quick Ratio only.
WBA' s Quick Ratio Range Over the Past 10 Years
Min: 0.27  Med: 0.5 Max: 1.7
Current: 0.36
0.27
1.7
Days Inventory 35.80
WBA's Days Inventory is ranked higher than
52% of the 366 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 39.43 vs. WBA: 35.80 )
Ranked among companies with meaningful Days Inventory only.
WBA' s Days Inventory Range Over the Past 10 Years
Min: 33.45  Med: 46.32 Max: 56.03
Current: 35.8
33.45
56.03
Days Sales Outstanding 19.37
WBA's Days Sales Outstanding is ranked lower than
56% of the 278 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 16.58 vs. WBA: 19.37 )
Ranked among companies with meaningful Days Sales Outstanding only.
WBA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 11.04  Med: 14.88 Max: 24.17
Current: 19.37
11.04
24.17
Days Payable 51.70
WBA's Days Payable is ranked higher than
59% of the 264 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 45.06 vs. WBA: 51.70 )
Ranked among companies with meaningful Days Payable only.
WBA' s Days Payable Range Over the Past 10 Years
Min: 28.73  Med: 34.47 Max: 51.7
Current: 51.7
28.73
51.7

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.35
WBA's Dividend Yield % is ranked higher than
61% of the 497 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.93 vs. WBA: 2.35 )
Ranked among companies with meaningful Dividend Yield % only.
WBA' s Dividend Yield % Range Over the Past 10 Years
Min: 0.96  Med: 1.82 Max: 3.11
Current: 2.35
0.96
3.11
Dividend Payout Ratio 0.31
WBA's Dividend Payout Ratio is ranked higher than
71% of the 294 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.32 vs. WBA: 0.31 )
Ranked among companies with meaningful Dividend Payout Ratio only.
WBA' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.24  Med: 0.36 Max: 0.64
Current: 0.31
0.24
0.64
3-Year Dividend Growth Rate 6.10
WBA's 3-Year Dividend Growth Rate is ranked lower than
57% of the 190 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 7.70 vs. WBA: 6.10 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
WBA' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 3.8  Med: 13.6 Max: 26
Current: 6.1
3.8
26
Forward Dividend Yield % 2.44
WBA's Forward Dividend Yield % is ranked higher than
54% of the 470 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.22 vs. WBA: 2.44 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 3.31
WBA's 5-Year Yield-on-Cost % is ranked higher than
62% of the 535 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.97 vs. WBA: 3.31 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
WBA' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.35  Med: 2.56 Max: 4.38
Current: 3.31
1.35
4.38
3-Year Average Share Buyback Ratio 4.40
WBA's 3-Year Average Share Buyback Ratio is ranked lower than
63% of the 214 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: -0.50 vs. WBA: 4.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
WBA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -4.9  Med: 0 Max: 4.4
Current: 4.4
-4.9
4.4

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.79
WBA's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
72% of the 212 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.56 vs. WBA: 0.79 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
WBA' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.72  Med: 2.53 Max: 19.52
Current: 0.79
0.72
19.52
Price-to-Intrinsic-Value-DCF (Earnings Based) 1.01
WBA's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
62% of the 58 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.39 vs. WBA: 1.01 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
WBA' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.43  Med: 1.1 Max: 2.87
Current: 1.01
0.43
2.87
Price-to-Median-PS-Value 0.91
WBA's Price-to-Median-PS-Value is ranked higher than
61% of the 312 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.11 vs. WBA: 0.91 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
WBA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.63  Med: 1.24 Max: 5.81
Current: 0.91
0.63
5.81
Price-to-Peter-Lynch-Fair-Value 1.39
WBA's Price-to-Peter-Lynch-Fair-Value is ranked lower than
81% of the 110 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.73 vs. WBA: 1.39 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
WBA' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.57  Med: 1.89 Max: 10.26
Current: 1.39
0.57
10.26
Earnings Yield (Greenblatt) % 7.23
WBA's Earnings Yield (Greenblatt) % is ranked higher than
58% of the 376 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 5.71 vs. WBA: 7.23 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
WBA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.4  Med: 7.4 Max: 14.7
Current: 7.23
3.4
14.7
Forward Rate of Return (Yacktman) % 16.46
WBA's Forward Rate of Return (Yacktman) % is ranked higher than
62% of the 255 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 9.05 vs. WBA: 16.46 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
WBA' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 5.1  Med: 13.5 Max: 23
Current: 16.46
5.1
23

More Statistics

Revenue (TTM) (Mil) $134,590.00
EPS (TTM) $ 5.43
Beta0.83
Volatility30.95%
52-Week Range $59.07 - 86.31
Shares Outstanding (Mil)943.44

Analyst Estimate

Aug19 Aug20 Aug21
Revenue (Mil $) 136,327 140,722 145,627
EBIT (Mil $) 7,867 8,380 8,490
EBITDA (Mil $) 9,559 10,115 10,498
EPS ($) 6.35 7.06 7.34
EPS without NRI ($) 6.35 7.06 7.34
EPS Growth Rate
(Future 3Y To 5Y Estimate)
4.30%
Dividends per Share ($) 1.74 1.81 1.89

Piotroski F-Score Details

Piotroski F-Score: 77
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}